Details for Patent: 8,063,043

« Back to Dashboard

Which drugs does patent 8,063,043 protect, and when does it expire?

Patent 8,063,043 protects ODOMZO and is included in one NDA.

This patent has thirty-nine patent family members in thirty-five countries.

Summary for Patent: 8,063,043

Title:	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
Abstract:	Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.
Inventor(s):	Bajwa; Joginder (Elmwood Park, NJ), de la Cruz; Marilyn (Matawan, NJ), Dodd; Stephanie Kay (Ayer, MA), Waykole; Liladhar Murlidhar (Succasunna, NJ), Wu; Raeann (Pine Brook, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/061,572
Patent Claim Types: see list of patent claims	Compound; Composition;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance
Sun Pharm Inds Inc	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015	RX	Yes	Yes	8,063,043	► Subscribe	Y	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,063,043

PCT Information
PCT Filed	September 15, 2009	PCT Application Number:	PCT/US2009/056918
PCT Publication Date:	March 25, 2010	PCT Publication Number:	WO2010/033481

International Patent Family for Patent: 8,063,043

Country	Document Number	Estimated Expiration
Argentina	073591	► Subscribe
Australia	2009293444	► Subscribe
Canada	2736751	► Subscribe
China	102159570	► Subscribe
Colombia	6351744	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,063,043

« Back to Dashboard

Summary for Patent: 8,063,043

Glossary

Foreign Priority and PCT Information for Patent: 8,063,043

International Patent Family for Patent: 8,063,043

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Get our Free Drug Patent Bulletin